Back to Resource Center / Insights / Posted on 06-28-2024
The conversation around the cost and coverage of GLP-1 agonist (or GLP-1s) drugs for weight loss is one we frequently have with our clients. With less than 43% of employers covering these drugs for weight loss and major insurers and State Plans pulling back coverage due to cost, the financial implications are significant. However, the potential benefits of coverage extend beyond weight loss, including delaying or preventing other obesity-related comorbidities such as cardiovascular disease, diabetes, sleep apnea, arthritis, and cancer. Considering drug insurance coverage for obesity drugs requires a careful evaluation for businesses aiming to support employee health and manage long-term healthcare costs. While these drugs can help offer significant health benefits, you must weigh the financial implications, and ensure proper program support to maximize effectiveness and safety.
What is a GLP-1 agonist Drug?
Initially developed to help treat Type 2 diabetes, GLP-1 (Glucagon-Like Peptide-1) agonists play a crucial role in regulating blood sugar levels. These drugs mimic the GLP-1 hormone, naturally produced in the intestines, which plays several critical roles in blood sugar regulation. GLP-1 drugs help lower blood sugar and reduce appetite. They increase insulin, slow down how fast the stomach empties and can make users feel full, which helps with weight loss and managing diabetes. Because of their effectiveness in lowering blood sugar and their impact on weight loss, GLP-1 drugs have gained popularity for treating obesity, leading to their approval for weight loss by regulatory agencies like the FDA.
Risks and Implications
Prior Authorization
For organizations, instituting a pre-authorization requirement before blanketly covering weight-loss drugs is critical. It helps ensure the drugs are prescribed judiciously, aligning with the individual’s medical needs and overall treatment plan. This step promotes thoughtful decision-making, preventing unnecessary medication use and potential risks.
Consider the following criteria:
- Participants who qualify as obese based on specific BMI measurements must also have at least one additional, related health condition
- Participants commit to a structured weight management program, which includes behavior management coaching and nutrition counseling
- Participants are required to commit to essential lifestyle and behavior changes to receive the medication
- Quantity limits and day supply limits be instituted
Contrastingly, obesity, historically viewed as a lifestyle issue, has often been excluded from pharmacy benefit coverage by many plan sponsors. However, the rise of GLP-1s has prompted a reevaluation of this stance. The high cost of these medications complicates decision-making for employers, necessitating a balanced approach.
In this complex landscape, it’s vital for organizations to consider their employees’ well-being thoughtfully. Trusting the expertise of healthcare providers is paramount in navigating coverage decisions, ensuring that those genuinely in need of weight management support receive appropriate coverage and care.
Key Takeaways
The landscape of GLP-1s for weight management is evolving rapidly, prompting employers to reassess their strategies for obesity in the years ahead. Confronting the obesity epidemic is a long-term challenge that necessitates substantial cost and societal shifts. It will not happen without significant cost and social change. Considering drug insurance coverage for obesity drugs requires a thoughtful balance between potential health advantages and financial considerations.
Back to Insight Center
View More Insights
Overview of the FTC’s Proposed Settlement with Express Scripts
On February 4, 2026, the Federal Trade Commission accepted a consent agreement for public comment regarding a settlement with Express Scripts, Inc. and its affiliated entities (collectively “ESI”). Once the consent order is issued by the Commission, it carries the force of law. The settlement resolves the lawsuit filed by the Commission against ESI regarding […]
What is a PBM Audit & Why You Might Need One in 2026
While PBM arrangements remain complex, the real question for organizations heading into 2026 is clear: How do you ensure your contracts are performing as promised? Hear from Ethica Pharmacy Advisors as we break down what a pharmacy benefits audit really is and why it’s one of the most powerful tools employers need to take control […]
Preparing for PBM Transparency Mandates: What Employers Must Know About New Federal Compliance Rules
Recent legislative and regulatory updates are shaping new PBM transparency and disclosure requirements, and Ethica Pharmacy Advisors is here to outline the compliance considerations for employers. On January 30, 2026, the Department of Labor (DOL) released proposed rules (“Improving Transparency into Pharmacy Benefit Manager Fee Disclosure”) developed pursuant to Executive Order 14273 and supported under […]
View All +
Let’s make it make sense.
Pharmacy benefits clarity begins with our market analysis where we reveal data-driven insights and identify opportunities to help you make more informed decisions.